Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback